Characterization of splenic glycosaminoglycans accumulated in vivo in experimentally induced amyloid-susceptible and amyloid-resistant mice

Scandinavian Journal of Immunology

Volumn 60, Issue 6, 2004, Pages 574-583

  Sugumaran, G ^a,b   Elliott Bryant, R ^a,b   Phung, N ^a,b   Vitseva, O ^a,b   Kuberan, B ^c   Lech, M ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID A PROTEIN; CHONDROITIN SULFATE; DERMATAN SULFATE; DISACCHARIDE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; PROTEOGLYCAN;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SULFATION;

AMYLOIDOSIS; ANIMALS; GENETIC PREDISPOSITION TO DISEASE; GLYCOPROTEINS; GLYCOSAMINOGLYCANS; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MICE; MICE, INBRED CBA; PROTEOGLYCANS; SERUM AMYLOID A PROTEIN; SILVER NITRATE; SPLEEN;

EID: 10844269667     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01516.x     Document Type: Article

References (36)

1. Kisilevsky R, Fraser P. Proteoglycans and amyloid fibrillogenesis. Ciba Found Symp 1996;199:58-67.
2. Kisilevsky R. The relation of proteoglycans, serum amyloid P and apo E to amyloidosis, current status. Amyloid 2000;7:23-5.
3. Kisilevsky R. Amyloidogenesis - unquestioned answers and unanswered questions. J Struct Biol 2000;30:99-108.
4. Snow AD, Wight TN. Proteoglycans in the parhogenesis of Alzheimer's disease and other amyloidoses. Neurobiol Aging 1989;10:481-97.
5. Magnus JH, Stenstad T. Proteoglycans and the extracellular matrix in amyloidosis. Amyloid 1997;4:121-34.
6. Kisilevsky R. Amyloidosis: a familiar problem in the light of current pathogenetic developments. Lab Invest 1983;49:381-92.
7. Axelrad MA, Kisilevsky R, Wilmer J, Chen SJ, Skinner M. Further characterization of amyloid-enhancing factor. Lab Invest 1982;47:139-46.
8. Sipe JD, McAdam KPWJ, Uchino F. Biochemical evidence for the biphasic development of experimental amyloidosis. Lab Invest 1978;38:110-4.
9. Sipe JD, Carreras I, Gonnerman WA, Carhcart ES, De Beer MC, De Beer FC. Characterization of the inbred CE/J mouse strain as amyloid resistant. Am J Pathol 1993;143:1480-5.
10. Ancsin JB, Kisilevsky R. The heparin/HS binding site on apoSAA. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 1999;274:7172-81.
11. McCubbin WD, Kay CM, Narindasorasak S, Kisilevsky R. Circular dichroism and fluorescence studies on two murine SAA proteins. Biochem J 1988;256:775-83.
12. Yu J, Zhu H, Guo J-T, deBeer FC, Kindy MS. Expression of mouse amyloid apolipoptoteinSAA1.1 in CE/J mice: isoform specific effects on amyloidogenesis. Lab Invest 2000;80:1797-806.
13. Lyon AW, Narindrasorasak S, Young ID et al. Co-deposition of basement membrane components during the induction of murine splenic AA amyloid. Lab Invest 1991;64:785-90.
14. Snow AD, Willmer J, Kisilevsky R. A close ultrastructural relationship between sulfated proteoglycans and AA amyloid fibrils. Lab Invest 1987;57:687-98.
15. Ailles L, Kisilevsky R, Young ID. Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis. Lab Invest 1993;69:443-8.
16. Snow AD, Bramson R, Mar H, Wight TN, Kisilevsky R. A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. J Histochem Cytochem 1991;39:1321-30.
17. Inoue S, Kisilevsky R. A high resolution ultrastructural study of experimental murine AA amyloid. Lab Invest 1996;74:670-83.
18. Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 1991;60:443-76.
19. Nakato H, Kimata K. Heparan sulfate fine structure and specificity of proteoglycan functions. Biochim Biophys Acta 2002;1573:312-8.
20. Shriver Z, Liu D, Saisekharan R. Emerging views of heparan sulfate glycosaminoglycan structure/activity relationships modulating dynamic biological functions. Trends Cardiovasc Med 2002;12:71-7.
21. Linker A, Carney HC. Presence and role of glycosaminoglycans in amyloidosis. Lab Invest 1987;57:297-305.
22. Lyon AW, Anastassiades T, Kisilevsky R. In vivo analysis of murine serum sulfate metabolism and splenic glycosaminoglycan biosynthesis during acute inflammation and amyloidosis. J Rheumatol 1993;20:1108-13.
23. Stenstad T, Magnus JH, Husby G. Characterization of proteoglycans associated with mouse splenic AA amyloidosis. Biochem J 1994;303:663-70.
24. Lindahl B, Lindahl U. Amyloid-specific heparan sulfate from human liver and spleen. J Biol Chem 1997;272:26091-4.
25. Fuxe K, Chadi G, Tinner B, Agnati LF, Pettersson R, David G. On the regional distribution of heparan sulfate proteoglycan immuno-reactivity in the rat brain. Brain Res 1994;636:131-8.
26. Elliott-Bryant R, Cathcart ES. Amyloid enhancing factor and dietary transmission in accelerated amyloid A amyloidosis. Clin Immunol Immunopathol 1998;88:65-9.
27. Elliott-Bryant R, Silbert JE, Sugumaran G. SAA, an acute phase protein, modulates proteoglycan synthesis in cultured murine peritoneal macrophages. Biochem Biophys Res Commun 1999;261:298-301.
28. Sugumaran G, Humphries DE, Silbert JE. Microsomal sulfation of proteochondroitin, chondroitin and chondroitin oligosaccharides. Methods Enzymol 1989;179:422-7.
29. Kuberan B, Lech M, Zhang L, Wu ZL, Beeler DL, Rosenberg RD. Analysis of heparan sulfate oligosaccharides with ion pair-reverse phase capillary high performance liquid chromatography-microelectrospray ionization time-of-flight mass spectrometry. J Am Chem Soc 2002;124:8707-18.
30. Wien TN, Omtvedt LA, Landsverk T, Husby G. Characterization of proteoglycans and glycosaminoglycans in splenic AA amyloid induced in mink. Scand J Immunol 2000;52:576-83.
31. Snow AD, Kisilevsky R, Stephens C, Anastassiades T. Characterization of tissue and plasma GAGs during experimental AA amyloidosis and acute inflammation. Lab Invest 1987;56:665-75.
32. U-Hansen L, Wik T, Kjellen L, Berg E, Forsdahl F, Kolset SO. Proteoglycan metabolism in normal and inflammatory human macrophages. Blood 1993;82:2880-9.
33. Bai X, Esko JD. An animal cell mutant defective in hepatan sulfate hexuronic acid 2-O-sulfation. J Biol Chem 1996;271:17711-7.
34. Merry CLR, Bullock SL, Swan DC et al. The molecular phenotype of heparan sulfate in the Hs2st-/-mutant mouse. J Biol Chem 2001;276:35429-34.
35. Norling B, Westermark GT, Westermark P. Immunohistochemical identification of heparan sulfate proteoglycan in secondary systemic amyloidosis. Clin Exp Immunol 1988;73:333-7.
36. Moss J, Shore I, Woodrow D. AA glomerular amyloid. An ultrastructural immunogold study of the colocalization of heparan sulfate proteoglycan and P component with amyloid fibrils together with changes in distribution of type IV collagen and fibronectin. Histopathology 1994;24:427-35.